While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitche | Eli ...

After earmarking a major chunk of change last year to bulk up in peptide production, European CDMO CordenPharma is putting ...

Less than a month after unveiling a peptide expansion at its production site in Mourenx, CDMO Axplora has hit the gas on a ...

The FDA has sent its first untitled letter of 2025, hitting Edenbridge Pharmaceuticals with a notice after assessin | The FDA ...

Shortly after making an M&A play to break into the CDMO business, Granules’ manufacturing bona fides have come under fire in ...

As Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once ...

Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...

As layoffs continue to strike biopharma outfits big and small, life sciences technology and service provider Cytiva is ...

ZoomRx has dug into its data to see what messages resonate with healthcare professionals (HCPs) at different stages | ZoomRx ...